Sarepta Therapeutics

Clarametyx Biosciences Appoints Renowned Experts to Augment Strategic and Scientific Advisory Boards

Retrieved on: 
tisdag, maj 28, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Biogen, Shionogi, Annamalai University, General partnership, Genentech, Biochemistry, Sarepta Therapeutics, Takeda Oncology, Biofilm, Flagship Pioneering, Palani, University, Therapy, Virginia Commonwealth University, Infection, MBA, Biophysics, MD, Takeda Pharmaceutical Company, Executive, Management

Dr. Palaniappan previously served as the Executive Vice President and Chief Technology Officer at Aruvant Sciences.

Key Points: 
  • Dr. Palaniappan previously served as the Executive Vice President and Chief Technology Officer at Aruvant Sciences.
  • His early career included leadership positions at Millennium Pharmaceuticals (acquired by Takeda), Biogen, Nexstar Pharmaceuticals (acquired by Gilead), and Par Pharmaceuticals.
  • He is currently a Managing Partner and Co-Founder of Trekk Venture Partners and serves on multiple public and private company boards.
  • Mr. Westberg received his MBA from the University of California, Berkeley and his BA from the University of California, San Diego.

Cell and Gene Therapies in CNS Disorders Research Report 2024: Pricing and Reimbursement Assessment, Current Treatment Options, Likelihood of Approval and Phase, Future Sales - Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
fredag, maj 10, 2024
Biotechnology, Genetics, Health, Stem Cells, Cell, Novartis, Myenteric plexus, Sarepta Therapeutics, Investment, DSM-IV codes, Central nervous system disease, Therapy, MLD, Onasemnogene abeparvovec, DMD, CGT, SMA, Duchenne, Growth, Gene, CNS, Duchenne muscular dystrophy, Environment, CALD, Central nervous system, Vaccine

Gene therapies will dominate the CGT market in CNS disorders.

Key Points: 
  • Gene therapies will dominate the CGT market in CNS disorders.
  • Overview of cell and gene therapies (CGT) in CNS Disorders.
  • Currently, there are eight cell and gene therapies (CGT) on the market for various central nervous system (CNS) disorders.
  • This includes three gene therapies, two gene-modified cell therapies, and three conditionally approved cell therapies.

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

Retrieved on: 
fredag, maj 3, 2024
Health, Neurology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Neuromuscular disease, SRPT, National academy, DSM-IV codes, Hospital, Muscular dystrophy, Book, SMA, Cell, Duchenne, Disease, TIME, Patient, Sarepta Therapeutics, Gene, Society, Nationwide, Duchenne muscular dystrophy, Head, Therapy, Global health, Pharmaceutical industry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.
  • The TIME100 Health list recognizes the impact, innovation, and achievement of the world’s most influential individuals in health.
  • In addition to recognition on the TIME100 Health list, Dr. Mendell is a 2024 recipient of the King Faisal Prize Laureate in Medicine.
  • He is also a published author of more than 400 peer-reviewed articles and books about skeletal muscle disease, peripheral nerve disorders and gene therapy.

IRA Capital Acquires 237,000 Square-Foot Life Science/R&D Campus in Columbus

Retrieved on: 
fredag, april 12, 2024
Interstate Highway System, FDA, Hospital, PPD, Research, Ohio State University, University of Wisconsin–Madison, Duchenne muscular dystrophy, University, Sarepta Therapeutics, Gene, Acquisition, Abbott Laboratories, Nationwide Children's Hospital, GMP, Easton Town Center, IRA, Pharmaceutical industry

Irvine, California--(Newsfile Corp. - April 11, 2024) - IRA Capital ("IRA"), a Southern California-based real estate private equity firm, is pleased to announce the acquisition of a 237,000 square-foot life science campus consisting of four, 3-story interconnected buildings located within Columbus Ohio's highly desired Easton submarket.

Key Points: 
  • Irvine, California--(Newsfile Corp. - April 11, 2024) - IRA Capital ("IRA"), a Southern California-based real estate private equity firm, is pleased to announce the acquisition of a 237,000 square-foot life science campus consisting of four, 3-story interconnected buildings located within Columbus Ohio's highly desired Easton submarket.
  • Sarepta specializes in genetic medicines for rare diseases and has four FDA approved drugs treating Duchenne Muscular Dystrophy, including its flagship treatment Elevydis.
  • Mr. Kasm explained that "Life Science companies with a presence in markets like Madison and Columbus benefit from lower operating costs and can leverage local fundamental drivers that generate efficiency.
  • IRA closed the acquisition on an all-cash basis and is actively pursuing additional life science opportunities.

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Retrieved on: 
onsdag, april 17, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Dravet syndrome, Gilead Sciences, College, Employment, Growth, Disease, Eteplirsen, Patient, Sarepta Therapeutics, Holy Cross, Marketing, Therapy, Autoimmunity, Vertex Pharmaceuticals, Pharmaceutical industry

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer.

Key Points: 
  • Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer.
  • As Chief Commercial Officer and a member of Stoke’s leadership team, Mr. Hoitt will be responsible for overseeing the Company’s global commercial strategy for STK-001.
  • "Jason brings deep expertise and a proven track record in successfully driving commercial strategies for novel new medicines and accelerating growth for companies as they transition to the commercial stage,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics.
  • Prior to Provention Bio, Mr. Hoitt served as Chief Commercial Officer at Dova Pharmaceuticals and led all commercial efforts including launch strategy and execution for DOPTELET® (avatrombopag) for chronic immune thrombocytopenia.

Parent Project Muscular Dystrophy Celebrates 30th Anniversary with Launch of PPMD Together Meeting Series in Cincinnati, Ohio

Retrieved on: 
onsdag, april 17, 2024
City, Hope, PTC Therapeutics, Today, Series, Empowerment, Becker muscular dystrophy, Parent, Research, Human, Catalyst Pharmaceuticals, Policy, Family, PPMD, Sarepta Therapeutics, Diagnosis, Duchenne muscular dystrophy, Grandparent, Therapy

CINCINNATI, April 17, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), proudly marks its 30th anniversary at the launch of the PPMD Together meeting series, taking place April 19-20, 2024, in Cincinnati, Ohio. Founded three decades ago by a small group of passionate parents and grandparents within the Duchenne community, PPMD has grown into a beacon of hope, driven by the unwavering dedication of parents, families, and individuals living with Duchenne and Becker.

Key Points: 
  • CINCINNATI, April 17, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , proudly marks its 30th anniversary at the launch of the PPMD Together meeting series, taking place April 19-20, 2024, in Cincinnati, Ohio.
  • In April 1994, Cincinnati served as the birthplace of PPMD, where a handful of determined families joined forces to confront the challenges posed by Duchenne.
  • PPMD selected the location and date of the first PPMD Together meeting to celebrate the 30th anniversary of the organization in its hometown of Cincinnati, April 19-20, 2024.
  • Sponsorship for the PPMD Together meeting has been provided by Catalyst Pharmaceuticals, Edgewise Therapeutics, NS Pharma, Pfizer, PTC Therapeutics, and Sarepta Therapeutics in accordance with PPMD's Corporate Relations Policy .

Autolus Therapeutics Announces Changes to its Board of Directors

Retrieved on: 
måndag, april 1, 2024
Cubist Pharmaceuticals, DBV Technologies, MB, Alnylam Pharmaceuticals, Harvard Medical School, University of Cambridge, Faculty, Imperial College London, Development, GSK plc, Biologics license application, Hematology, Patient, ALL, Merck, Bristol Myers Squibb, Marketing, Biogen, Doctor of Philosophy, Bates College, Oxford Biomedica, Sarepta Therapeutics, Pharmaceutical medicine, Therapy, Swedish Orphan Biovitrum, Royal college, FDA, BLA, Autoimmunity, Economics, Food, Pharmaceutical industry

John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.

Key Points: 
  • John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.
  • We wish John much success with his new projects,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
  • He is currently a director of Alnylam Pharmaceuticals and chair of Dunad Therapeutics and Gulf of Maine Research Institute.
  • Mr. Bonney has served as a director with many companies previously including Celgene, Kaleido Biosciences, Magenta Therapeutics, Bristol Myers Squibb, Sarepta Therapeutics and Syros Pharmaceuticals.

Global Cell Counting Market to Hit $15.72 Billion by 2029, Fueled by Advancements in Cell Biology and Therapy - ResearchAndMarkets.com

Retrieved on: 
fredag, mars 29, 2024
Research, Technology, University, Genetics, Artificial Intelligence, Education, Science, Nanotechnology, Biotechnology, Stem Cells, Other Technology, Health, Other Science, Automation, Quality control, Interdisciplinarity, Acute lymphoblastic leukemia, Growth, Prevalence, Application, Novartis, Patient, Conditional sentence, Cell biology, Lung, Concha bullosa, Hospital, Artificial intelligence, National Cancer Institute, AI, Regenerative medicine, Duchenne muscular dystrophy, Therapy, DEB, Miniaturization, Sarepta Therapeutics, CGT, FDA, DMD, Tisagenlecleucel, PDUFA, Pharmaceutical industry

The global cell counting market was valued at US$9.98 billion in 2023 and is expected to reach US$15.72 billion by 2029.

Key Points: 
  • The global cell counting market was valued at US$9.98 billion in 2023 and is expected to reach US$15.72 billion by 2029.
  • Advancements in cell biology, biotechnology, and medical research are driving demand for precise cell counting, especially with the rise of personalized medicine and regenerative therapies.
  • PDUFA dates for therapies could translate into an order book boost for the cell counting players in the market, resulting in market growth.
  • The global cell counting market is consolidated, with top five players holding approximately 70% share of the market.

Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance

Retrieved on: 
tisdag, april 2, 2024
Sarepta Therapeutics, Interest, Growth, CFO, CCO, CSO, Person

LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.

Key Points: 
  • LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.
  • Søren Tulstrup, President and CEO, Hansa Biopharma, said: "Q1 represents a strong start to the year with solid product sales for the second quarter in a row and the best IDEFIRIX® product sales recorded in a quarter.
  • The Company will publish Q1 2024 results on April 18, 2024.
  • The information was submitted for publication, through the contact persons set out below, at 07:00: CET on April 2, 2024.

Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance

Retrieved on: 
tisdag, april 2, 2024
Sarepta Therapeutics, Interest, Growth, CFO, CCO, CSO, Person

LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.

Key Points: 
  • LUND, Sweden, April 2, 2024 /PRNewswire/ -- Hansa Biopharma AB (STO: HNSA) expects to report revenue of approximately SEK 54m for Q1 ending March 31, 2024 (preliminary and unaudited), consisting of SEK 48m in product sales and SEK 6m in revenue recognition primarily related to its agreement with Sarepta Therapeutics, Inc. Revenue growth during the first quarter 2024 was driven by product sales in the Company's largest markets including France, UK, and Germany, as well as initial sales in Belgium.
  • Søren Tulstrup, President and CEO, Hansa Biopharma, said: "Q1 represents a strong start to the year with solid product sales for the second quarter in a row and the best IDEFIRIX® product sales recorded in a quarter.
  • The Company will publish Q1 2024 results on April 18, 2024.
  • The information was submitted for publication, through the contact persons set out below, at 07:00: CET on April 2, 2024.